Investors have activated a new "crowdfunding" website for life sciences deals. Dubbed VentureHealth, the website aims to expand the number of deep-pocketed players who are actively investing in medical technology startups as some traditional sources wilt.
To translate Big Data in genomics into useful healthcare products, entrepreneurs might have roll up their sleeves an invent their own solutions like the Srinivasan brothers have.
The London-based drug giant has partnered with veteran life sciences investors at Avalon Ventures to bankroll a crop of drug-hunting startups in San Diego, with GSK committing the bulk of the alliance's $495 million to fuel the new companies.
The Redwood City, CA-based startup reports that Sierra Ventures has led a $6.25 million round of Series B money, with more backers expected to step up with capital to fatten the deal in the coming months.
A new genomics upstart has taken flight to create a new way of mobilizing personal DNA data. Miinome aims to offer a unique personal genetic marketplace, serving as a broker between peoples' genetic info and buyers of the data.
Despite some technological and initial financing feats under their belts, young software and bioinformatics outfits need to answer some key questions. For example, who pays?
Merck KGaA has entrusted its R&D portfolio for inflammatory bowel diseases to a start-up Swiss company it's spinning out of the wreckage resulting from its R&D restructuring. A division of the German pharma company, Merck Serono, is seeding Calypso Biotech with more than $3 million and turning over supervision of its investment to the division's venture arm.
The biotech landscape is covered with startup efforts with cancer drugs, but when Dr. Patrick Soon-Shiong announces one, the business world stops and listens.
Is genome interpretation approaching "bubble" status as startups rise all around to find what matters in massive amounts of DNA data? Bio-IT World editor and genomics chronicler Kevin Davies questioned the chief executive of one of the higher-profile outfits from the field, Cypher Genomics, to find out what makes the startup stand out from the crowd.
The biotech field is covered with startup efforts with cancer drugs, but when Dr. Patrick Soon-Shiong announces one the business world stops and listens.